CompletedNCT00791401
Official study titleThe Pharmacokinetics of ER OROS Paliperidone in Subjects With Varying Degrees of Impaired Renal Function (Mild, Moderate, and Severe) as Compared to Subjects With Normal Renal Function
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–75
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT00791284
Official study titlePharmacokinetics of Paliperidone in Subjects With Moderate Hepatic Impairment as Compared to Subjects With Normal Hepatic Function.
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–75
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedACTRN12614000429651
Official study titleA Cross-Sectional, Case-Control Study of the Physical Health Status of Vietnam Veterans with and without Post-Traumatic Stress Disorder (PTSD) and Investigation of Genetics of PTSD.
This study has finished and is no longer accepting participants.
In GreenslopesPTSDObservational study
- Countries
- Australia
- Sponsor
- Returned Services League (RSL) Queensland
CompletedNCT00892541
Official study titleInvestigation of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS Paliperidone in Healthy Male Subjects
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–55
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedACTRN12622001535763
Official study titleA study of the psychological, cognitive and physiological effects of Psychedelic Medicines on healthy individuals (ASSESS)
This study has finished and is no longer accepting participants.
In AustraliaMental healthInterventional studyAges 21–70
- Countries
- Australia
- Sponsor
- Monarch Mental Health Group
CompletedNCT03017781
Official study titleAn Observational Longitudinal Study in Offspring of Parents With Bipolar Disorder to Evaluate the Relationship of Impairment in Psychosocial Functioning With the Manifestation of Mood Symptoms Over 24 Months
This study has finished and is no longer accepting participants.
Multiple locations, including Culver CityBipolarityObservational studyAges 15–25
- Countries
- United States
- Sponsor
- Janssen Research & Development, LLC
CompletedNCT00250354
About this title
A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation
Read the official source — NCT00250354Official study titleThe Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years
This study has finished and is no longer accepting participants.
Location not clearly listedADHDMedication studyAges 5–12
- Countries
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
CompletedNCT00266552
About this title
A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation
Read the official source — NCT00266552Official study titleThe Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years
This study has finished and is no longer accepting participants.
Location not clearly listedADHDMedication studyAges 5–12
- Countries
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
CompletedNCT00132678
About this title
A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes
Read the official source — NCT00132678Official study titleA Randomized, Double-blind, Placebo-controlled Study to Explore the Efficacy and Safety of Risperidone Long-acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar 1 Disorder, With Open-label Extension
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockBipolarityMedication studyAges 18–65
- Countries
- United States, Austria, India, + 7 others
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT00477672
About this title
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Read the official source — NCT00477672Official study titleA Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease
This study has finished and is no longer accepting participants.
Multiple locations, including GilbertSchizophreniaMedication studyAges 40+
- Countries
- United States, France, United Kingdom, + 4 others
- Sponsor
- ACADIA Pharmaceuticals Inc.
CompletedNCT02035553
Official study titleA Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease
This study has finished and is no longer accepting participants.
In LondonSchizophreniaMedication studyAges 50+
- Countries
- United Kingdom
- Sponsor
- ACADIA Pharmaceuticals Inc.